Status:
COMPLETED
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. T...
Eligibility Criteria
Inclusion
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Body mass index (BMI) greater than or equal to 30.0 kg/m\^2
- New York Heart Association (NYHA) Class II-IV
- Left ventricular ejection fraction (LVEF) greater than or equal to 45 percentage at screening
Exclusion
- A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
- Haemoglobin A1c (HbA1c) greater than or equal to 6.5 percentage (48 mmol/mol) based on latest available value from medical records, no older than 3 months or if unavailable a local measurement at screening
Key Trial Info
Start Date :
March 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 18 2023
Estimated Enrollment :
529 Patients enrolled
Trial Details
Trial ID
NCT04788511
Start Date
March 16 2021
End Date
April 18 2023
Last Update
December 5 2025
Active Locations (146)
Enter a location and click search to find clinical trials sorted by distance.
1
Eastern Shore Rsrch Inst, LLC
Fairhope, Alabama, United States, 36532
2
National Heart Institute Cal
Beverly Hills, California, United States, 90211
3
Keck Medical Center of USC - Outpatient Clinic
Los Angeles, California, United States, 90033
4
Lundquist Inst-Biomed Innovtn
Torrance, California, United States, 90502